Skip to main content

Table 4 Objective response rates by clinical characteristics, HER2 status, and p53 status

From: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Variable Number of patientsa Response rate (%) P valueb
Age    0.045
   >50 years 108 29  
   ≤50 years 50 14  
Performance status    0.81
   0 77 23  
   1 or 2 80 25  
ER    0.056
   Positive 70 17  
   Negative 71 31  
PR    0.51
   Positive 64 22  
   Negative 71 27  
ER/PR    0.22
   At least 1 positive 81 20  
   Both negative 59 29  
Number of metastatic sites    0.50
   0–2 139 25  
   >2 17 18  
Disease-free interval    0.10
   ≤2 years 101 20  
   >2 years 57 32  
Prior adjuvant chemotherapy    0.83
   Yes 94 24  
   No 61 23  
HER2 CBll    0.96
   Positive 30 23  
   Negative 126 24  
HER2 FISH    0.70
   Positive 37 22  
   Negative 109 25  
HER2 HercepTest    0.026
   Positive: 2–3 46 35  
   Negative: 0–1 105 18  
HER2 HercepTest    0.98
   Positive: 3 30 23  
   Negative: 0–2 121 23  
p53 IHC    0.79
   Positive 56 23  
   Negative 89 21  
p53 Mutation    0.55
   Present 42 21  
   Absent 103 26  
  1. aNot all patients could be evaluated for a response, and those who could not be evaluated have been excluded. b P values are for comparisons of the proportion of patients with a response to paclitaxel in each group. ER, estrogen receptor; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; PR, progesterone receptor.